Implantica AG (IMP-A-SDB.ST)
SEK 26.85
(-5.95%)
SEK 26.85
(-5.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 91 Thousand EUR | 121.62% |
| 2022 | -421 Thousand EUR | 51.44% |
| 2021 | -867 Thousand EUR | 19.72% |
| 2020 | -1.08 Million EUR | 10.15% |
| 2019 | -1.2 Million EUR | -6941.6% |
| 2018 | 17.56 Thousand EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 197 Thousand EUR | -17.92% |
| 2024 Q1 | 240 Thousand EUR | 47.24% |
| 2023 Q1 | -16 Thousand EUR | 78.38% |
| 2023 FY | 91 Thousand EUR | 121.62% |
| 2023 Q4 | 163 Thousand EUR | 311.69% |
| 2023 Q3 | -77 Thousand EUR | -466.67% |
| 2023 Q2 | 21 Thousand EUR | 231.25% |
| 2022 Q4 | -74 Thousand EUR | 39.84% |
| 2022 Q3 | -123 Thousand EUR | -16.04% |
| 2022 Q2 | -106 Thousand EUR | 10.17% |
| 2022 FY | -421 Thousand EUR | 51.44% |
| 2022 Q1 | -118 Thousand EUR | 43.81% |
| 2021 Q3 | -226 Thousand EUR | -13.57% |
| 2021 Q2 | -199 Thousand EUR | 14.22% |
| 2021 Q1 | -232 Thousand EUR | 18.02% |
| 2021 Q4 | -210 Thousand EUR | 7.08% |
| 2021 FY | -867 Thousand EUR | 19.72% |
| 2020 FY | -1.08 Million EUR | 10.15% |
| 2020 Q2 | -232 Thousand EUR | 18.6% |
| 2020 Q4 | -283 Thousand EUR | -1.07% |
| 2020 Q3 | -280 Thousand EUR | -20.69% |
| 2020 Q1 | -285 Thousand EUR | 5.63% |
| 2019 Q3 | -306 Thousand EUR | 0.0% |
| 2019 Q4 | -302 Thousand EUR | 1.31% |
| 2019 FY | -1.2 Million EUR | -6941.6% |
| 2018 FY | 17.56 Thousand EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 98.282% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 99.97% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 99.97% |
| Arcoma AB | 11.07 Million SEK | 99.178% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 99.935% |
| BICO Group AB (publ) | 1.83 Billion SEK | 99.995% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 99.964% |
| CellaVision AB (publ) | 463.04 Million SEK | 99.98% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | 96.964% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 100.32% |
| C-Rad AB (publ) | 66.01 Million SEK | 99.862% |
| Duearity AB (publ) | -4.17 Million SEK | 102.178% |
| Dignitana AB (publ) | 58.97 Million SEK | 99.846% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 100.218% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.999% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 100.181% |
| Iconovo AB (publ) | 17.57 Million SEK | 99.482% |
| Integrum AB (publ) | 690.56 Thousand SEK | 86.822% |
| Luxbright AB (publ) | -2.79 Million SEK | 103.254% |
| Mentice AB (publ) | 236.38 Million SEK | 99.962% |
| OssDsign AB (publ) | 83.64 Million SEK | 99.891% |
| Paxman AB (publ) | 12.61 Million SEK | 99.279% |
| Promimic AB (publ) | 38.51 Million SEK | 99.764% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 100.179% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 99.433% |
| ScandiDos AB (publ) | 47.55 Million SEK | 99.809% |
| Sectra AB (publ) | 557.55 Million SEK | 99.984% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 99.916% |
| Senzime AB (publ) | 8.33 Million SEK | 98.909% |
| SpectraCure AB (publ) | -9.22 Million SEK | 100.987% |
| Stille AB | 132.17 Million SEK | 99.931% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 99.995% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 99.978% |